MICROENCAPSULATED TRANSDERMAL PENETRATION ENHANCERS

微囊透皮渗透促进剂

• 批准号: 3507970
• 负责人: KELLY L SMITH
• 金额: $ 24.02万
• 依托单位: BEND RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-03-01 至 1994-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3507970
• 关键词: biological models; biological transport; bradykinin; cortisol; ethanol; hydropathy; inhibitor /antagonist; membrane permeability; method development; microcapsule; oleate; pharmacokinetics; piroxicam; skin; skin irritation /irritant; slow release drug; topical drug application; water; water solubility

DESCRIPTION: (Adapted from the Applicant's Abstract). The goal of this program is to use controlled release technology to develop improved penetration enhancers for use in transdermal or topical drug-delivery systems. Transdermal drug delivery offers several advantages over other routes of drug administration, but has been successfully commercialized for only a limited number of drugs. The primary factor responsible for this limited use of transdermal drug delivery is the low transdermal flux of most drugs. Although penetration enhancers have been identified that increase the transdermal penetration of specific drugs, the utility of such enhancers is limited by rapid clearance from the application site through transdermal permeation and/or evaporation. It is stated that in Phase I of this program, the feasibility of controlled-release penetration enhancers to increase the drug flux was demonstrated for a model drug/enhancer combination. Both the quantity of drug delivered and the duration of delivery were significantly increased over the quantity and duration observed without controlled release. The goal in Phase II is to demonstrate the utility of this approach for drugs and enhancers that are representative of a wide range of potential transdermal products.

描述：（根据申请人的摘要进行了改编）。 目标的目标 程序是使用受控释放技术来发展改进 用于透皮或局部药物交付的渗透增强剂 系统。 透皮药物提供比其他的几个优势 药物管理途径，但已成功商业化 只有有限的药物。 负责这一点的主要因素 透皮药物输送的使用有限是透皮通量的低 大多数药物。 尽管已经确定了渗透增强剂 增加特定药物的透皮渗透，这种效用 增强剂受应用网站通过快速清除的限制 透皮渗透和/或蒸发。 有人指出，在第一阶段 该程序，受控释放渗透增强剂的可行性 为了增加药物的药物/增强剂，证明了药物通量 组合。 递送药物的数量和持续时间 交付的数量和持续时间显着增加 观察到没有受控释放。 第二阶段的目标是 证明这种方法对药物和增强剂的实用性 代表广泛的潜在透皮产品。